|
Editor’s Note: What if you could claim a stake in a technology set to become 100X bigger than Bitcoin… starting with just $2? Click here to see the details from investing legend and Washington D.C. insider Jeff Brown — the man who picked Bitcoin, Tesla, and Nvidia before they exploded higher. Or read more below. Dear Reader, From PayPal to Tesla… From SpaceX to Dogecoin… Elon Musk has the uncanny ability to see around corners… And make millions for those who mirror his moves. Which is why days ago… When I noticed Elon is doubling down on a technology I call “W.T.E.” — I couldn’t ignore it. This has nothing to do with self-driving cars… AI… or space rockets. It’s his latest secretive investment. (It involves a technology he tried to deploy during his tenure at DOGE – but was shut down by the extreme left.) And based on my six year analysis of this tech sector… I believe it could be 90 times bigger than AI… 120 times bigger than the internet… And 1,900 times bigger than Bitcoin. Yahoo Finance reports it: “May Unlock $400 Trillion.” To see what has Elon’s full attention… And how to invest in the technology Bloomberg calls “unavoidable” — click here for the full details. Jeff Brown Today’s editorial pick for you A Hantavirus Outbreak Boosting Moderna (MRNA) Stock? Don’t Bet on It.Posted On May 13, 2026 by Joshua Enomoto 
With lingering memories of COVID-19 still in the air, it’s only natural that the latest hantavirus scare is accelerating positive sentiments for Moderna (NASDAQ: MRNA). On Friday, MRNA stock jumped nearly 12% on hantavirus vaccine research. That brings the security up over 84% on a year-to-date basis. While it’s tempting to jump on the Moderna bandwagon, considering the COVID catalyst, traders will want to exercise healthy skepticism. Table of ContentsTo be clear, I’m not suggesting that Moderna is an irrelevant pharmaceutical enterprise. Far from it, the company enjoys several promising therapeutic pipelines. However, I believe it would be a mistake to bid up the mRNA stock simply on the basis of the hantavirus. When looking at the facts, a mismatch exists between the fear of the virus and the probabilistic risks to the general public. According to the UN World Health Organization (WHO), the risk of hantavirus spread to the general population is “absolutely low.” Indeed, the threat is a nuanced argument. While the virus has a high mortality rate, the risk of exposure to the average person is extremely limited, in part because of transmission difficulty. The Andes strain that’s in question here requires very close, prolonged contact to jump between people. In other words, unless you are cleaning out a long-abandoned shed or going on a birding expedition in rural Argentina, your exposure risk is negligible. Better yet, one of the best ways people can help prevent infection is to address rodent infestations. Basic cleanliness and hygiene — along with other common-sense practices — can go a very long way. That also segues into another concern about buying MRNA stock simply on the basis of a possible hantavirus outbreak — the convenience factor. Because the transmission risk is low to begin with, the preventative measures are convenient. Generally speaking, getting pricked with needles isn’t an enjoyable experience. Therefore, a vaccine may be considered an overkill solution. Bid Up MRNA Stock? ‘No Thanks’ Says the Smart MoneyObviously, no one knows for sure what the future may hold regarding potential public health crises. And given the fiasco of the global COVID-19 response, it’s understandable that many people are skeptical about the assertions coming from even respected health agencies. That said, it’s interesting that the smart money isn’t biting on Moderna stock. How do I know? When looking at the volatility skew for the June 18 expiration date, the positioning of implied volatility (IV) readings across the strike price spectrum tells the tale. From the current spot price to the right end of the axis, IV for call options rises in an almost linear fashion. Basically, bullish traders are paying a higher premium than they would be under normal circumstances. Fundamentally, we’re talking about simple economics here: there’s more demand for call options and thus call sellers are more than happy to collect the exaggerated premium. However, these call sellers are most likely covered call sellers by institutional investors who are long MRNA stock. They believe in Moderna but not in the hantavirus hype. Subsequently, the smart money is using the premiums to buy protective puts on MRNA stock. You’ll notice that in the volatility skew for June 18, put IV stands above the equivalent call IV. Technically, this dynamic usually occurs when a security is hard to borrow or when there is a high cost of carry. In my assessment, these sophisticated traders are betting that the hanta hype will fade. It’s also worth pointing out that the put skew for strike prices right below the spot is extremely flat, with the skew only rising sharply on the extremely low end. While it’s impossible to make absolute pronouncements about trader sentiments, this chart signals that the smart money likely doesn’t believe MRNA stock is going to collapse. Sure, the far out-the-money (OTM) puts are in place in case stuff happens. But the most likely outcome — at least what the institutional folks are showing — is that MRNA stock will soon revert to the mean. This is a PAID ADVERTISEMENT provided to the subscribers of StockEarnings Free Newsletter. Although we have sent you this email, StockEarnings does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above. Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe. StockEarnings, Inc
|
